Drug Trial Radar · NCT03205163
A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)
Last checked: Nov 19, 2026Latest source record: Apr 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Aug 28, 2017
Primary completion
Nov 12, 2018
Study completion Nov 12, 2018
Sponsor
- Lead sponsor
- Bioverativ, a Sanofi companySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jul 2, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose was to assess the safety and tolerability of a single intravenous (IV) administration of BIVV001 in adult previously treated patients (PTPs) with severe hemophilia A.
Conditions
- Hemophilia A
Interventions
Advate (Low Dose)Biological
Participants received a single IV low dose of Advate 25 IU/kg.
Advate (High Dose)Biological
Participants received a single IV high dose of Advate 65 IU/kg.
BIVV001 (Low Dose)Biological
Participants received single IV low dose of BIVV001 25 IU/kg.
BIVV001 (High Dose)Biological
Participants received single IV high dose of BIVV001 65 IU/kg.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (TEAE) and Treatment Emergent Serious Adverse Event (TESAE) During Advate Treatment PeriodTime frame: Up to Day 3 for Advate 25 IU/kg; up to Day 4 for Advate 65 IU/kg
- Number of Participants With Treatment Emergent Adverse Events (TEAE) and Treatment Emergent Serious Adverse Event (TESAE) During BIVV001 Treatment PeriodTime frame: Up to 28 days after BIVV001 administration
- Number of Participants With Clinically Significant Abnormalities in Laboratory Tests During Advate Treatment PeriodTime frame: Up to Day 3 for Advate 25 IU/kg; up to Day 4 for Advate 65 IU/kg
- Number of Participants With Clinically Significant Abnormalities in Laboratory Tests During BIVV001 Treatment PeriodTime frame: Up to 28 days after BIVV001 administration
- Percentage of Participants With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda AssayTime frame: Up to 28 days after BIVV001 administration
Locations
10 sites in 2 countries. Site status is shown where the registry gives one.
University of California Los Angeles Medical Center
Los Angeles, California
Indiana Hemophilia and Thrombosis Center
Indianapolis, Indiana
University of Iowa Hospitals & Clinics
Iowa City, Iowa
Michigan State University
East Lansing, Michigan
Mississippi Center for Advanced Medicine
Madison, Mississippi
Hemophilia Center of Western PA
Pittsburgh, Pennsylvania
University of Washington
Seattle, Washington
Nara Medical University Hospital
Kashihara-shi, Nara, Japan
Tokyo Medical University Hospital
Shinjuku-Ku, Tokyo-To, Japan
Ogikubo Hospital
Tokyo, Tokyo-To, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.